Furthermore, prior research has shown that CLDN1 promotes drug resistance of NSCLC to cisplatin, showing how CLDN1 is correlated with poor prognosis of NSCLC (Fagerberg et al., 2014). This evidence concerns the gene CLDN1 and non-small cell lung carcinoma.